Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 2,174 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 2,174 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $46.65, for a total value of $101,417.10. Following the sale, the insider owned 113,549 shares of the company’s stock, valued at $5,297,060.85. This represents a 1.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, May 6th, Jula Inrig sold 311 shares of Travere Therapeutics stock. The stock was sold at an average price of $43.95, for a total value of $13,668.45.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $45.00, for a total value of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.61, for a total value of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $44.70 on Thursday. The stock has a market capitalization of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. The business has a 50 day simple moving average of $32.59 and a two-hundred day simple moving average of $32.83. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. Travere Therapeutics, Inc. has a 1-year low of $13.88 and a 1-year high of $48.61.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to analysts’ expectations of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm’s revenue for the quarter was up 55.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.47) EPS. On average, research analysts predict that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year?over?year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long?term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre?arranged Rule 10b5?1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500?share sale) can create short?term selling pressure or investor concern. Example SEC filing: CEO Form 4

Analyst Ratings Changes

A number of brokerages have recently commented on TVTX. Wall Street Zen cut Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. HC Wainwright lifted their target price on Travere Therapeutics from $47.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. JPMorgan Chase & Co. dropped their target price on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, March 25th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $47.83.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Travere Therapeutics by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock worth $158,059,000 after acquiring an additional 619,085 shares during the last quarter. State Street Corp raised its position in Travere Therapeutics by 47.8% during the 4th quarter. State Street Corp now owns 4,756,666 shares of the company’s stock valued at $181,752,000 after purchasing an additional 1,538,827 shares in the last quarter. Perceptive Advisors LLC raised its position in Travere Therapeutics by 12.7% during the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock valued at $163,469,000 after purchasing an additional 483,565 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Travere Therapeutics by 27.4% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock valued at $41,203,000 after purchasing an additional 599,102 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Travere Therapeutics by 28.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock valued at $85,849,000 after purchasing an additional 494,665 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.